Day 1 | Day 2 | Short Courses | Download Brochure
Scientific Advisory Board
Joseph M. Carroll, Ph.D., Associate Director, Business Development, Knight Cancer Institute, Oregon Health & Science University (OHSU)
Christopher L. Corless, M.D., Ph.D., Professor, Pathology and Medical Director, Knight Cancer Institute, Oregon Health & Science University
Joe Gray, Ph.D., Associate Director for Translational Research for the Knight Cancer Institute, Oregon Health & Science University (OHSU); Director, OHSU Center for Spatial Systems Biomedicine (OCSSB) and Gordon Moore Chair of Biomedical Engineering, OHSU School of Medicine
TUESDAY, AUGUST 20
7:30 am Registration and Morning Coffee
8:30 Chairperson’s Opening Remarks
Joe Gray, Ph.D., Associate Director, Translational Research for the Knight Cancer Institute, Oregon Health & Science University (OHSU); Director, OHSU Center for Spatial Systems Biomedicine (OCSSB) and Gordon Moore Chair of Biomedical Engineering, OHSU School of Medicine
8:40 KEYNOTE PRESENTATION: Total Cancer Care: Developing a Molecular Markers Approach for Targeted Therapies
William S. Dalton, M.D., Ph.D., CEO, M2Gen; Director, Personalized Medicine Institute, H. Lee Moffitt Cancer Center & Research Institute
Critical to using molecular markers to match patients to the best therapies is the development of a biorepository in parallel with the development of a data warehouse and an information system containing patient’s clinical and molecular data. The Total Cancer Care™ Protocol, now with >95K consented patients, >33K tumors and >16K genetic profiles, provides a foundation to accomplish the goal of targeted therapies.
9:10 Multiplex Mutation Screening and other Assay Technologies in Support of a Personalized Cancer Medicine Registry
Christopher L. Corless, M.D., Ph.D., Professor, Pathology and Medical Director, Knight Cancer Institute, Oregon Health & Science University
Making personalized cancer care a reality requires novel approaches to finding treatment targets in cancers, because current single-gene assays are not adequate for the growing spectrum of actionable mutations. This presentation will focus on the opportunities and challenges of introducing new multiplexed and next-gen sequencing technologies into clinical laboratories.
9:40 Paradigm's Prospective Clinical Trial on mRNA and Protein Expression for Selecting Targeted Oncology Therapy
Robert J. Penny, M.D., Ph.D., CEO, Paradigm
Paradigm will review its founder's previous prospective clinical trial results in which clinical outcomes of standard of care treatment were compared to targeted therapy based on molecular pathway findings . Validation of paraffin and frozen tissue mRNA findings will also be presented.
10:10 Coffee Break
10:55 Chairperson’s Remarks
11:00 Next-Generation Sequencing and Target-Based Approach in Early-Phase Clinical Trials in Cancer
Filip Janku, M.D., Ph.D., Assistant Professor, Investigational Cancer Therapeutics, (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center
This presentation will outline the role of novel comprehensive genomic technologies in early-phase clinical trials in cancer. In addition, this presentation will suggest how early-phase clinical trials can be expanded from dose finding to proof-of-concept studies.
11:30 Innovations in Next-Generation Sequencing: Enhancing Understanding of Tumor Biology
Steve Shak, M.D., CMO, Genomic Health
12:00 pm The Role of Clinical Grade Next-Generation Sequencing in Cancer Diagnostics: Foundation Medicine’s Clinical Experience
Gary Palmer, M.D., J.D., MBA, MPH, Senior Vice President, Medical Affairs and Commercial Development, Foundation Medicine
Our experience with targeted next-generation sequencing in the clinic: the pitfalls and the promises. What we have learned from our first 2,000+ cases that will optimize the value of targeted next-generation sequencing to the clinician, the patient, and the payor.
12:30 Sponsored Presentation (Opportunity Available)
12:45 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own
2:00 Session Break
2:15 Chairperson’s Remarks
Christopher L. Corless, M.D., Ph.D., Professor, Pathology and Medical Director, Knight Cancer Institute, Oregon Health & Science University
2:20 Keynote Presentation: Identifying Tumor Intrinsic and Extrinsic Predictive Markers
Joe Gray, Ph.D., Associate Director, Translational Research for the Knight Cancer Institute, Oregon Health & Science University (OHSU); Director, OHSU Center for Spatial Systems Biomedicine (OCSSB) and Gordon Moore Chair of Biomedical Engineering, OHSU School of Medicine
This talk will focus on new approaches to identification of molecular features intrinsic to tumors and from the extrinsic tumor micro environments that interact to determine responses to pathway targeted therapies. The talk will link results from analysis of well characterized in vitro models to clinical performance.
2:50 Functionalizing the Cancer Genome: A Mutation-Driven View
Gordon Mills, M.D., Ph.D., Chairman, Department of Systems Biology, Chief, Section of Molecular Therapeutics; Professor of Medicine and Immunology; and Anne Rife Cox Chair in Gynecology, MD Anderson Cancer Center
Genomic aberrations have proven to be amongst the strongest and most robust biomarkers. However, emerging data suggests that we need to evaluate the consequences and effects of each aberration independently. For example, both activating and inactivating mutations in BRAF can alter patient outcome and require different therapies. I will describe a high-throughput platform to assess the consequences of specific point mutations and a method to identify therapeutic liabilities.
3:20 Sponsored Presentation (Opportunity Available)
3:35 Refreshment Break in the Exhibit Hall with Poster Viewing
4:10 Use of Whole Genome Outlier Analysis to Identify Occult Biomarkers of Drug Response
David B. Solit, M.D., Elizabeth & Felix Rohatyn Chair, Memorial Sloan Kettering Cancer Center
The use of next-generation sequencing methods including whole genome sequencing to identify the molecular basis of drug sensitivity and resistance will be discussed.
4:40 Use of the Microenvironment to Develop Diagnostic and Prognostic Multigene Profiles for Prostate Cancer
Dan Mercola, M.D., Ph.D., Professor, Pathology and Laboratory Medicine; Director, Translational Cancer Biology University of California at Irvine
The gene activity changes in the microenvironment of prostate cancer can be used to form multigene profiles for diagnosis and for prognosis. Diagnosis based on gene expression in stroma by detection of "presence of tumor" and indicates the need for rapid re-biopsy. Prognosis is classification as early or no relapse following radical prostatectomy. The methods of profile development will be discussed.
5:10 Wine and Cheese Pairing Welcome Reception in the Exhibit Hall with Poster Viewing
6:10 Close of Day
Day 1 | Day 2 | Short Courses | Download Brochure